YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.

Jun Guo,Wei Zhang,Yan Shu,Haijun Yang,Mengke Wang,Zhi Ye,Shiqiong Huang,Peng Zhu,Qing Li,Honghao Zhou

doi:10.3389/fphar.2021.744578

Abstract

Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits of lenvatinib. Therefore, understanding the mechanism of resistance is necessary for improving lenvatinib efficacy. YRDC promotes the proliferation of hepatocarcinoma cells via regulating the activity of the RAS/RAF/MEK/ERK pathway, which was the primary pathway of the anticancer effect of lenvatinib. The purpose of this study is to investigate whether YRDC modulates the sensitivity of lenvatinib in hepatocarcinoma cells. Using the CCK-8 cell viability assay, wound-healing assay and clone formation assay in cell models, and xenograft assay in null mouse, we demonstrated that Huh7 cells with YRDC knockdown showed decreased susceptibility to lenvatinib than their control cells. Furthermore, we found that lenvatinib inhibited the expression of YRDC in a time-dependent manner. This effect may aggravate resistance to lenvatinib in hepatocarcinoma cells and may be an underlying cause of resistance, which emerges soon after lenvatinib initial treatment. To investigate how YRDC modulates the sensitivity of lenvatinib, we assessed the effect of tRNA with different t6A levels on the translation of the KRAS gene by in vitro rabbit reticulocyte translation system and measured the expression levels of the KRAS gene by western blot together with qPCR. We found that YRDC regulates the protein translation of KRAS in cell models, and the tRNA with low t6A modification level reduces the translation of the KRAS in the in vitro translation system. These results suggested that YRDC mediates the resistance of lenvatinib in hepatocarcinoma cells via modulating the translation of the KRAS. In this study, YRDC was confirmed to be a potential novel predictive biomarker of lenvatinib sensitivity in HCC.

Highlights

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide and has a higher growth incidence (Bray et al, 2018)
Wound-healing assays revealed that the migration inhibition of lenvatinib to Huh7 cells was decreased by YRDC knockdown (Figures 2A–C)
We firstly found that the YRDC expression was associated with the sensitivity of lenvatinib in hepatocellular carcinoma cells

Summary

Introduction

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide and has a higher growth incidence (Bray et al, 2018). The estimated incidence of new cases is approximately 500,000–1,000,000 annually, causing 600,000 mortalities globally per year. Curative treatment of these patients, such as locoregional therapies and surgical therapies, can achieve 5-year survival rates up to 60–70% (European Association for the Study of the Liver, 2018; Llovet et al, 2018; Nault et al, 2018). There are few effective therapies for patients with advanced stage or with tumor progression after locoregional, leading to an extremely poor prognosis. Traditional chemotherapy drugs have little effect on survival in patients with advanced HCC (European Association for the Study of the Liver, 2018)

Objectives

Methods

Results

Conclusion